Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Azrak, Shousong Cao, H. Slocum, K. Toth, F. Durrani, M. Yin, L. Pendyala, Wanghai Zhang, H. McLeod, Y. Rustum (2004)
Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor XenograftsClinical Cancer Research, 10
J. Byrne, M. Jajja, Allison Schorzman, Amanda Keeler, J. Luft, W. Zamboni, J. Desimone, J. Yeh (2016)
Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinomaProceedings of the National Academy of Sciences, 113
Y Cui, JA Brosnan, A Blackford, S Sur, RH Hruban, KW Kinzler, B Vogelstein, A Maitra, LA Diaz, CA Iacobuzio-Donahue, JR Eshleman (2012)
Genetically defined subsets of human pancreatic cancer demonstrate unique in vitro chemosensitivityClin Cancer Res, 18
Y. Na, Seung-mi Kim, K. Jung, S. Yang, Y. Hong, M. Ryu, S. Ro, D. Cho, J. Kim, D. Jin, Jung Lee, Tae Kim (2010)
Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.Oncology reports, 24 6
Nobuaki Kurata, H. Fujita, K. Ohuchida, K. Mizumoto, P. Mahawithitwong, H. Sakai, M. Onimaru, T. Manabe, T. Ohtsuka, Masao Tanaka (2011)
Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil.International journal of oncology, 39 2
M. Pikal (1992)
The role of electroosmotic flow in transdermal iontophoresisAdvanced Drug Delivery Reviews, 46
Huali Wu, J. Infante, V. Keedy, Suzanne Jones, E. Chan, J. Bendell, Wooin Lee, Whitney Kirschbrown, B. Zamboni, S. Ikeda, H. Kodaira, M. Rothenberg, H. Burris, W. Zamboni (2015)
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsInternational Journal of Nanomedicine, 10
A. Neesse, H. Algül, D. Tuveson, T. Gress (2015)
Stromal biology and therapy in pancreatic cancer: a changing paradigmGut, 64
C. Louvet, A. Coudray, C. Tournigand, Sophie Prévost, E. Raymond, A. Gramont, Michel Chazard, C. Gespach (2000)
Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude miceAnti-Cancer Drugs, 11
B. Büchel, P. Rhyn, S. Schürch, Claudia Bühr, U. Amstutz, C. Largiadèr (2013)
LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.Biomedical chromatography : BMC, 27 1
Yunfeng Cui, Jacqueline Brosnan, A. Blackford, Surojit Sur, R. Hruban, K. Kinzler, B. Vogelstein, A. Maitra, L. Diaz, C. Iacobuzio-Donahue, J. Eshleman (2012)
Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro ChemosensitivityClinical Cancer Research, 18
H. Yi, Yeong-Jin Choi, K. Kang, J. Hong, Ruby Pati, M. Park, I. Shim, C. Lee, Song-Cheol Kim, D. Cho (2016)
A 3D-printed local drug delivery patch for pancreatic cancer growth suppression.Journal of controlled release : official journal of the Controlled Release Society, 238
Y. Kalia, A. Naik, J. Garrison, R. Guy (2004)
Iontophoretic drug delivery.Advanced drug delivery reviews, 56 5
T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J. Raoul, S. Gourgou-Bourgade, C. Fouchardière, J. Bennouna, J. Bachet, F. Khemissa-Akouz, D. Péré-Vergé, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. Montoto-Grillot, M. Ducreux (2011)
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.The New England journal of medicine, 364 19
Laura Indolfi, M. Ligorio, D. Ting, Kristina Xega, A. Tzafriri, Francesca Bersani, N. Aceto, V. Thapar, B. Fuchs, V. Deshpande, A. Baker, C. Ferrone, D. Haber, R. Langer, Jeffrey Clark, E. Edelman (2016)
A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.Biomaterials, 93
P. Hammel, F. Huguet, J. Laethem, D. Goldstein, B. Glimelius, P. Artru, I. Borbath, O. Bouché, J. Shannon, T. André, L. Mineur, B. Chibaudel, F. Bonnetain, C. Louvet (2016)
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.JAMA, 315 17
J. Kleeff, C. Reiser, U. Hinz, Jeannine Bachmann, J. Debus, D. Jaeger, H. Friess, M. Büchler (2007)
Surgery for Recurrent Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 245
D. Melisi, Qianghua Xia, G. Paradiso, J. Ling, T. Moccia, C. Carbone, A. Budillon, J. Abbruzzese, P. Chiao (2011)
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.Journal of the National Cancer Institute, 103 15
K. Olive, Michael Jacobetz, Christian Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M. Goldgraben, Meredith Caldwell, D. Allard, K. Frese, G. DeNicola, C. Feig, C. Combs, Stephen Winter, Heather Ireland-Zecchini, S. Reichelt, W. Howat, A.-L. Chang, M. Dhara, Lifu Wang, F. Rückert, R. Grützmann, C. Pilarsky, K. Izeradjene, S. Hingorani, Pearl Huang, S. Davies, W. Plunkett, M. Egorin, R. Hruban, Nigel Whitebread, Karen McGovern, J. Adams, C. Iacobuzio-Donahue, J. Griffiths, D. Tuveson (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 324
B. Wallace, Adam Roberts, R. Pollet, J. Ingle, K. Biernat, S. Pellock, M. Venkatesh, Leah Guthrie, Sara O'Neal, Sara Robinson, M. Dollinger, Esteban Figueroa, Sarah McShane, Rachel Cohen, Jian Jin, S. Frye, W. Zamboni, C. Pepe-Ranney, S. Mani, L. Kelly, M. Redinbo (2015)
Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.Chemistry & biology, 22 9
G. Heestand, James Murphy, A. Lowy (2015)
Approach to patients with pancreatic cancer without detectable metastases.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 16
I. Garrido-Laguna, M. Hidalgo (2015)
Pancreatic cancer: from state-of-the-art treatments to promising novel therapiesNature Reviews Clinical Oncology, 12
Marc Kai, Amanda Keeler, Jillian Perry, Kevin Reuter, J. Luft, Sara O'Neal, W. Zamboni, J. DeSimone, J. DeSimone (2015)
Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle.Journal of controlled release : official journal of the Controlled Release Society, 204
Taís Gratieri, Y. Kalia (2014)
Targeted local simultaneous iontophoresis of chemotherapeutics for topical therapy of head and neck cancers.International journal of pharmaceutics, 460 1-2
Richard Moffitt, Raoud Marayati, Elizabeth Flate, Keith Volmar, S. Loeza, K. Hoadley, N. Rashid, Lindsay Williams, Samuel Eaton, Alexander Chung, Jadwiga Smyla, Judy Anderson, Hong Kim, D. Bentrem, M. Talamonti, C. Iacobuzio-Donahue, Michael Hollingsworth, Jen Yeh (2015)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaNature genetics, 47
J. Byrne, Mohammad Jajja, A. O'Neill, L. Bickford, Amanda Keeler, Nabeel Hyder, K. Wagner, A. Deal, Ryan Little, R. Moffitt, Colleen Stack, M. Nelson, Christopher Brooks, William Lee, J. Luft, M. Napier, David Darr, C. Anders, R. Stack, J. Tepper, Andrew Wang, W. Zamboni, J. Yeh, J. Desimone (2015)
Local iontophoretic administration of cytotoxic therapies to solid tumorsScience Translational Medicine, 7
Purpose Effective treatment of patients with locally advanced pancreatic cancer is a significant unmet clinical need. One major hurdle that exists is inadequate drug delivery due to the desmoplastic stroma and poor vascularization that is char- acteristic of pancreatic cancer. The local iontophoretic delivery of chemotherapies provides a novel way of improving treatment. With the growing practice of highly toxic combination therapies in the treatment of pancreatic cancer, the use of iontophoresis for local delivery can potentiate the anti-cancer effects of these therapies while sparing unwanted toxicity. The objective of this study was to investigate the impact of formulation on the electro-transport of the FOLFIRINOX regimen for the development of a new treatment for pancreatic cancer. Methods Three formulations of the FOLFIRINOX regimen (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) were generated at a fixed pH of 6.0 and were referred to as formulation A (single drug solution with all four drugs combined), formulation B (two drug solutions with two drugs per solution), and formulation C (four individual drug solutions). Anodic iontophoresis of the three different formulations was evaluated in orthotopic patient-derived xenografts of pancreatic cancer. Results Iontophoretic transport of the FOLFIRINOX drugs was characterized according to organ exposure after a
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Mar 30, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.